Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels

Fu, Xihua; Lou, Haibo; Chen, Fang; Gao, Xueping; Lin, Zhuo

doi:10.1007/s10238-019-00603-5

Cited by 3 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a baseline qAnti-HBc level of ≥ 3.1 log10 IU/mL was associated with higher rates of VR and SR in CHB patients treated with entecavir. However, the levels were lower than the results reported by previous studies 15 , 17 , 18 . Serum qAnti-HBc levels are closely related to host immune status and are strongly associated with hepatitis activity in CHB patients.…”

Section: Discussioncontrasting

confidence: 82%

“…Baseline qAnti-HBc could predict HBeAg seroconversion in CHB patients treated with IFNs or NA 14 – 18 . The present study evaluated dynamic changes in qAnti-HBc in CHB patients during 10 years of entecavir therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Many studies have shown that baseline qAnti-HBc levels could serve as a useful marker for predicting SR in HBeAg-positive CHB patients during Peg-IFN and NA therapies 14 – 17 . In 2020, Fu et al indicated that patients with baseline qAnti-HBc level ≥ 4.15log10 IU/mL and liver stiffness measurements ≥ 9.85 kPa had the highest rates of SR after 96 weeks of NA (entecavir, telbivudine or tenofovir disoproxil fumarate) therapy 18 . However, no studies have investigated the clinical value of qAnti-HBc levels for redefined VR (double-negative HBV DNA and RNA) following long-term NA therapy in CHB patients in real-life practice.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years

Zhang

Shi

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The predictive effect of quantitative anti-hepatitis B core on double-negative HBV DNA and RNA remains unstudied. We observed dynamic changes in this measure in chronic hepatitis B patients receiving entecavir for 10 years, evaluating its predictive value for double-negative HBV DNA and RNA. Twenty-seven chronic hepatitis B patients treated with entecavir for 10 years were enrolled in this study. Liver function, quantitative anti-hepatitis B core, hepatitis B surface and e antigens, HBV DNA and RNA were measured at baseline and each follow-up. Virological response was defined as double-negative HBV DNA and RNA; serological response was defined as hepatitis B e antigen seroconversion. After antiviral therapy, quantitative anti-hepatitis B core showed an overall downward trend. Patients with virological response had significantly higher quantitative anti-hepatitis B core levels than those without virological response at baseline. Patients with serological response also had higher quantitative anti-hepatitis B core levels than those without serological response at baseline and week 24. Baseline quantitative anti-hepatitis B core level was the only independent predictor for virological and serological responses. Baseline quantitative anti-hepatitis B core level was powerfully predictive of double-negative HBV DNA and RNA in chronic hepatitis B patients receiving long-term entecavir therapy.

show abstract

Section: Discussioncontrasting

confidence: 82%

Section: Discussionmentioning

confidence: 99%